A Strategy Towards the Generation of Testable Adverse Outcome Pathways for Nanomaterials

Manufactured nanomaterials (NMs) are increasingly used in a wide range of industrial applications leading to a constant increase in the market size of nano-enabled products. The increased production and use of NMs are raising concerns among different stakeholder groups with regard to their effects o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION 2021-01, Vol.38 (4), p.580-594
Hauptverfasser: Murugadoss, Sivakumar, Vrcek, Ivana Vinkovic, Pem, Barbara, Jagiello, Karolina, Judzinska, Beata, Sosnowska, Anita, Martens, Marvin, Willighagen, Egon L, Puzyn, Tomasz, Dusinska, Maria, Cimpan, Mihaela Roxana, Fessard, Valerie, Hoet, Peter H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 594
container_issue 4
container_start_page 580
container_title ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION
container_volume 38
creator Murugadoss, Sivakumar
Vrcek, Ivana Vinkovic
Pem, Barbara
Jagiello, Karolina
Judzinska, Beata
Sosnowska, Anita
Martens, Marvin
Willighagen, Egon L
Puzyn, Tomasz
Dusinska, Maria
Cimpan, Mihaela Roxana
Fessard, Valerie
Hoet, Peter H
description Manufactured nanomaterials (NMs) are increasingly used in a wide range of industrial applications leading to a constant increase in the market size of nano-enabled products. The increased production and use of NMs are raising concerns among different stakeholder groups with regard to their effects on human and environmental health. Currently, nanosafety hazard assessment is still widely performed using in vivo (animal) models, however the development of robust and reg­ulatory relevant strategies is required to prioritize and/or reduce animal testing. An adverse outcome pathway (AOP) is a structured representation of biological events that start from a molecular initiating event (MIE) leading to an adverse outcome (AO) through a series of key events (KEs). The AOP framework offers great advancement to risk assessment and regulatory safety assessments. While AOPs for chemicals have been more frequently reported, the AOP collection for NMs is limited. By using existing AOPs, we aimed to generate simple and testable strategies to predict if a given NM has the potential to induce a MIE leading to an AO through a series of KEs. Firstly, we identified potential MIEs or initial KEs reported for NMs in the literature. Then, we searched the identified MIE or initial KEs as keywords in the AOP-Wiki to find associated AOPs. Finally, using two case studies, we demonstrate how in vitro strategies can be used to test the identified MIE/KEs.
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_123456789_675289</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>123456789_675289</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_123456789_6752893</originalsourceid><addsrcrecordid>eNqNjL0OgjAYRRujiUZ9h29zMCb8SIGRGH8mNZGBranyIShQ0xaQt7eDg6N3OTc3N2dAJnZAg5UX0mT408dkrtTDMqGWY_vOhCQRXLTkGu89xKLjMlWgc4Q91mjmQtQgMohRaX4tEaK0RakQTo2-iQrhzHXe8V5BJiQceS0qo5IFL9WMjDIDnH85JYvdNt4cVs-mxKbFmqXqxW_IbMdde9QPQkZ9zwlCd0qW_z2Zfmv3f-8HGBlS1Q</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Strategy Towards the Generation of Testable Adverse Outcome Pathways for Nanomaterials</title><source>Lirias (KU Leuven Association)</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Murugadoss, Sivakumar ; Vrcek, Ivana Vinkovic ; Pem, Barbara ; Jagiello, Karolina ; Judzinska, Beata ; Sosnowska, Anita ; Martens, Marvin ; Willighagen, Egon L ; Puzyn, Tomasz ; Dusinska, Maria ; Cimpan, Mihaela Roxana ; Fessard, Valerie ; Hoet, Peter H</creator><creatorcontrib>Murugadoss, Sivakumar ; Vrcek, Ivana Vinkovic ; Pem, Barbara ; Jagiello, Karolina ; Judzinska, Beata ; Sosnowska, Anita ; Martens, Marvin ; Willighagen, Egon L ; Puzyn, Tomasz ; Dusinska, Maria ; Cimpan, Mihaela Roxana ; Fessard, Valerie ; Hoet, Peter H</creatorcontrib><description>Manufactured nanomaterials (NMs) are increasingly used in a wide range of industrial applications leading to a constant increase in the market size of nano-enabled products. The increased production and use of NMs are raising concerns among different stakeholder groups with regard to their effects on human and environmental health. Currently, nanosafety hazard assessment is still widely performed using in vivo (animal) models, however the development of robust and reg­ulatory relevant strategies is required to prioritize and/or reduce animal testing. An adverse outcome pathway (AOP) is a structured representation of biological events that start from a molecular initiating event (MIE) leading to an adverse outcome (AO) through a series of key events (KEs). The AOP framework offers great advancement to risk assessment and regulatory safety assessments. While AOPs for chemicals have been more frequently reported, the AOP collection for NMs is limited. By using existing AOPs, we aimed to generate simple and testable strategies to predict if a given NM has the potential to induce a MIE leading to an AO through a series of KEs. Firstly, we identified potential MIEs or initial KEs reported for NMs in the literature. Then, we searched the identified MIE or initial KEs as keywords in the AOP-Wiki to find associated AOPs. Finally, using two case studies, we demonstrate how in vitro strategies can be used to test the identified MIE/KEs.</description><identifier>ISSN: 1868-596X</identifier><identifier>EISSN: 1868-596X</identifier><language>eng</language><publisher>SPEKTRUM AKADEMISCHER VERLAG-SPRINGER-VERLAG GMBH</publisher><ispartof>ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2021-01, Vol.38 (4), p.580-594</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,780,784,27860</link.rule.ids></links><search><creatorcontrib>Murugadoss, Sivakumar</creatorcontrib><creatorcontrib>Vrcek, Ivana Vinkovic</creatorcontrib><creatorcontrib>Pem, Barbara</creatorcontrib><creatorcontrib>Jagiello, Karolina</creatorcontrib><creatorcontrib>Judzinska, Beata</creatorcontrib><creatorcontrib>Sosnowska, Anita</creatorcontrib><creatorcontrib>Martens, Marvin</creatorcontrib><creatorcontrib>Willighagen, Egon L</creatorcontrib><creatorcontrib>Puzyn, Tomasz</creatorcontrib><creatorcontrib>Dusinska, Maria</creatorcontrib><creatorcontrib>Cimpan, Mihaela Roxana</creatorcontrib><creatorcontrib>Fessard, Valerie</creatorcontrib><creatorcontrib>Hoet, Peter H</creatorcontrib><title>A Strategy Towards the Generation of Testable Adverse Outcome Pathways for Nanomaterials</title><title>ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION</title><description>Manufactured nanomaterials (NMs) are increasingly used in a wide range of industrial applications leading to a constant increase in the market size of nano-enabled products. The increased production and use of NMs are raising concerns among different stakeholder groups with regard to their effects on human and environmental health. Currently, nanosafety hazard assessment is still widely performed using in vivo (animal) models, however the development of robust and reg­ulatory relevant strategies is required to prioritize and/or reduce animal testing. An adverse outcome pathway (AOP) is a structured representation of biological events that start from a molecular initiating event (MIE) leading to an adverse outcome (AO) through a series of key events (KEs). The AOP framework offers great advancement to risk assessment and regulatory safety assessments. While AOPs for chemicals have been more frequently reported, the AOP collection for NMs is limited. By using existing AOPs, we aimed to generate simple and testable strategies to predict if a given NM has the potential to induce a MIE leading to an AO through a series of KEs. Firstly, we identified potential MIEs or initial KEs reported for NMs in the literature. Then, we searched the identified MIE or initial KEs as keywords in the AOP-Wiki to find associated AOPs. Finally, using two case studies, we demonstrate how in vitro strategies can be used to test the identified MIE/KEs.</description><issn>1868-596X</issn><issn>1868-596X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqNjL0OgjAYRRujiUZ9h29zMCb8SIGRGH8mNZGBranyIShQ0xaQt7eDg6N3OTc3N2dAJnZAg5UX0mT408dkrtTDMqGWY_vOhCQRXLTkGu89xKLjMlWgc4Q91mjmQtQgMohRaX4tEaK0RakQTo2-iQrhzHXe8V5BJiQceS0qo5IFL9WMjDIDnH85JYvdNt4cVs-mxKbFmqXqxW_IbMdde9QPQkZ9zwlCd0qW_z2Zfmv3f-8HGBlS1Q</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Murugadoss, Sivakumar</creator><creator>Vrcek, Ivana Vinkovic</creator><creator>Pem, Barbara</creator><creator>Jagiello, Karolina</creator><creator>Judzinska, Beata</creator><creator>Sosnowska, Anita</creator><creator>Martens, Marvin</creator><creator>Willighagen, Egon L</creator><creator>Puzyn, Tomasz</creator><creator>Dusinska, Maria</creator><creator>Cimpan, Mihaela Roxana</creator><creator>Fessard, Valerie</creator><creator>Hoet, Peter H</creator><general>SPEKTRUM AKADEMISCHER VERLAG-SPRINGER-VERLAG GMBH</general><scope>FZOIL</scope></search><sort><creationdate>20210101</creationdate><title>A Strategy Towards the Generation of Testable Adverse Outcome Pathways for Nanomaterials</title><author>Murugadoss, Sivakumar ; Vrcek, Ivana Vinkovic ; Pem, Barbara ; Jagiello, Karolina ; Judzinska, Beata ; Sosnowska, Anita ; Martens, Marvin ; Willighagen, Egon L ; Puzyn, Tomasz ; Dusinska, Maria ; Cimpan, Mihaela Roxana ; Fessard, Valerie ; Hoet, Peter H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_123456789_6752893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murugadoss, Sivakumar</creatorcontrib><creatorcontrib>Vrcek, Ivana Vinkovic</creatorcontrib><creatorcontrib>Pem, Barbara</creatorcontrib><creatorcontrib>Jagiello, Karolina</creatorcontrib><creatorcontrib>Judzinska, Beata</creatorcontrib><creatorcontrib>Sosnowska, Anita</creatorcontrib><creatorcontrib>Martens, Marvin</creatorcontrib><creatorcontrib>Willighagen, Egon L</creatorcontrib><creatorcontrib>Puzyn, Tomasz</creatorcontrib><creatorcontrib>Dusinska, Maria</creatorcontrib><creatorcontrib>Cimpan, Mihaela Roxana</creatorcontrib><creatorcontrib>Fessard, Valerie</creatorcontrib><creatorcontrib>Hoet, Peter H</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murugadoss, Sivakumar</au><au>Vrcek, Ivana Vinkovic</au><au>Pem, Barbara</au><au>Jagiello, Karolina</au><au>Judzinska, Beata</au><au>Sosnowska, Anita</au><au>Martens, Marvin</au><au>Willighagen, Egon L</au><au>Puzyn, Tomasz</au><au>Dusinska, Maria</au><au>Cimpan, Mihaela Roxana</au><au>Fessard, Valerie</au><au>Hoet, Peter H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Strategy Towards the Generation of Testable Adverse Outcome Pathways for Nanomaterials</atitle><jtitle>ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION</jtitle><date>2021-01-01</date><risdate>2021</risdate><volume>38</volume><issue>4</issue><spage>580</spage><epage>594</epage><pages>580-594</pages><issn>1868-596X</issn><eissn>1868-596X</eissn><abstract>Manufactured nanomaterials (NMs) are increasingly used in a wide range of industrial applications leading to a constant increase in the market size of nano-enabled products. The increased production and use of NMs are raising concerns among different stakeholder groups with regard to their effects on human and environmental health. Currently, nanosafety hazard assessment is still widely performed using in vivo (animal) models, however the development of robust and reg­ulatory relevant strategies is required to prioritize and/or reduce animal testing. An adverse outcome pathway (AOP) is a structured representation of biological events that start from a molecular initiating event (MIE) leading to an adverse outcome (AO) through a series of key events (KEs). The AOP framework offers great advancement to risk assessment and regulatory safety assessments. While AOPs for chemicals have been more frequently reported, the AOP collection for NMs is limited. By using existing AOPs, we aimed to generate simple and testable strategies to predict if a given NM has the potential to induce a MIE leading to an AO through a series of KEs. Firstly, we identified potential MIEs or initial KEs reported for NMs in the literature. Then, we searched the identified MIE or initial KEs as keywords in the AOP-Wiki to find associated AOPs. Finally, using two case studies, we demonstrate how in vitro strategies can be used to test the identified MIE/KEs.</abstract><pub>SPEKTRUM AKADEMISCHER VERLAG-SPRINGER-VERLAG GMBH</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1868-596X
ispartof ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2021-01, Vol.38 (4), p.580-594
issn 1868-596X
1868-596X
language eng
recordid cdi_kuleuven_dspace_123456789_675289
source Lirias (KU Leuven Association); DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals
title A Strategy Towards the Generation of Testable Adverse Outcome Pathways for Nanomaterials
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A22%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Strategy%20Towards%20the%20Generation%20of%20Testable%20Adverse%20Outcome%20Pathways%20for%20Nanomaterials&rft.jtitle=ALTEX-ALTERNATIVES%20TO%20ANIMAL%20EXPERIMENTATION&rft.au=Murugadoss,%20Sivakumar&rft.date=2021-01-01&rft.volume=38&rft.issue=4&rft.spage=580&rft.epage=594&rft.pages=580-594&rft.issn=1868-596X&rft.eissn=1868-596X&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E123456789_675289%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true